PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-16.72%
Both companies show declining cash positions (-16.72% vs GNPX's -41.96%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-16.72%
Below half of GNPX's -41.96%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Current Assets Growth compared to GNPX's zero value, indicating worse performance.
-19.08%
Below half of GNPX's -41.78%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-14.24%
Below half GNPX's 41.77%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.11%
Below half of GNPX's 18.68%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
0.5-0.75x GNPX's -33.18%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-4.20%
Less than half of GNPX's 26.40%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.87%
Less than half of GNPX's -14.17%. David Dodd sees fewer expansions in other current obligations.
18.79%
Less than half of GNPX's -40.66%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.79%
Less than half of GNPX's -40.66%. David Dodd sees far fewer liability expansions relative to competitor.
2.42%
Above 1.5x GNPX's 1.52%. Michael Burry suspects heavy new equity expansion or dilution.
-5.90%
1.25-1.5x GNPX's -5.31%. Bruce Berkowitz notes stronger reinvestment strategy.
-12.27%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-28.51%
0.75-0.9x GNPX's -31.87%. Bill Ackman wonders if competitor is growing equity faster.
-19.02%
0.5-0.75x GNPX's -33.18%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.72%
Less than half of GNPX's 41.96%. David Dodd sees better deleveraging or stronger cash buildup than competitor.